Vcare 2022 Annual Review

　　I. Corporate Development and Infrastructure

　　① Wholly-owned subsidiary Nanjing Vcare successfully acquired Hubei Tianshu Pharmaceutical Co., Ltd.

　　② CDMO Business Technology Center completed and operational.

　　③ Established new technology platform laboratories.

　　④ Built a new Innovative Drug Synthesis Technology Center.

　　II. Progress in Innovative Drug R&D Pipeline

　　① Vicagrel completed subject enrollment for key clinical trials.

　　② VC004 clinical trials advanced steadily with significant efficacy results.

　　③ VC005 obtained regulatory approval for multiple expanded indications.

　　④ Multiple preclinical projects progressed rapidly.

　　III. Drug R&D Services Sustained Growth

　　① CRO/CDMO service revenue exceeded RMB 300 million.

　　② New CRO/CDMO contracts signed valued at nearly RMB 500 million.

　　IV. Corporate Financing Status

　　① Successfully closed Series A financing totaling ~RMB 370 million.

　　② Completed Series B financing exceeding RMB 200 million.

　　V. Talent Development Initiatives

　　① Expanded workforce by 200+, reaching nearly 600 employees.

　　② Completed nearly 50 employee promotions.

　　③ Conducted ~80 employee training sessions.

　　④ Held management skills enhancement workshop.

　　⑤ Established strategic partnerships with multiple universities.

　　⑥ Launched 2nd employee equity incentive plan, covering ~120 employees.

　　VI. Awards & Honors

　　①Jiangsu Vcare Honored As: Nanjing Nurtured Unicorn Enterprise; Jiangsu 2022 Specialized, Refined, Unique, and Innovative SME; Top 30 in Nanjing High-Tech Zone Enterprise Innovation Index

　　②Nanjing Vcare Honored As: National Sci-Tech SME; Top 20 CRO Enterprises in China’s Pharmaceutical Industry